Adicet Bio, Inc. (ACET) stock
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.93−0.06 (-2.01%)
Close on Nov 12, 2026Market cap $27.43MP/E –Yield –
Adicet Bio cash
Cash and short-term investments held at the end of each period.
Adicet Bio's cash was $27.11M at Sep 30, 2026. For fiscal 2025 it was $38.92M, down 34.5% from the year before. The highest annual figure on record is $277.69M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.92M | -34.5% |
| FY2024 | Dec 31, 2024 | $59.40M | -62.8% |
| FY2023 | Dec 31, 2023 | $159.71M | -38.0% |
| FY2022 | Dec 31, 2022 | $257.66M | -7.2% |
| FY2021 | Dec 31, 2021 | $277.69M | +180.1% |
| FY2020 | Dec 31, 2020 | $99.14M | +8.4% |
| FY2019 | Dec 31, 2019 | $91.50M | +865.7% |
| FY2018 | Dec 31, 2018 | $9.48M | -74.4% |
| FY2017 | Dec 31, 2017 | $36.95M | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $27.11M | -6.8% |
| Q2 FY2026 | Jun 30, 2026 | $33.13M | -4.6% |
| Q1 FY2026 | Mar 31, 2026 | $36.25M | +28.8% |
| Q4 FY2025 | Dec 31, 2025 | $38.92M | -34.5% |
| Q3 FY2025 | Sep 30, 2025 | $29.10M | -85.6% |
| Q2 FY2025 | Jun 30, 2025 | $34.72M | -84.5% |
| Q1 FY2025 | Mar 31, 2025 | $28.13M | -82.4% |
| Q4 FY2024 | Dec 31, 2024 | $59.40M | -62.8% |
| Q3 FY2024 | Sep 30, 2024 | $202.07M | +10.3% |
| Q2 FY2024 | Jun 30, 2024 | $224.07M | +9.1% |
| Q1 FY2024 | Mar 31, 2024 | $159.71M | -31.1% |
| Q4 FY2023 | Dec 31, 2023 | $159.71M | -38.0% |
| Q3 FY2023 | Sep 30, 2023 | $183.26M | -35.2% |
| Q2 FY2023 | Jun 30, 2023 | $205.46M | -21.2% |
| Q1 FY2023 | Mar 31, 2023 | $231.64M | -16.6% |
| Q4 FY2022 | Dec 31, 2022 | $257.66M | -7.2% |
| Q3 FY2022 | Sep 30, 2022 | $282.68M | +47.1% |
| Q2 FY2022 | Jun 30, 2022 | $260.64M | +24.9% |
| Q1 FY2022 | Mar 31, 2022 | $277.88M | +24.4% |
| Q4 FY2021 | Dec 31, 2021 | $277.69M | +180.1% |
| Q3 FY2021 | Sep 30, 2021 | $192.23M | +77.8% |
| Q2 FY2021 | Jun 30, 2021 | $208.73M | +1042.8% |
| Q1 FY2021 | Mar 31, 2021 | $223.42M | +3213.9% |
| Q4 FY2020 | Dec 31, 2020 | $99.14M | +8.4% |
| Q3 FY2020 | Sep 30, 2020 | $108.12M | -7.8% |
| Q2 FY2020 | Jun 30, 2020 | $18.26M | -86.2% |
| Q1 FY2020 | Mar 31, 2020 | $6.74M | -95.3% |
| Q4 FY2019 | Dec 31, 2019 | $91.50M | +865.7% |
| Q3 FY2019 | Sep 30, 2019 | $117.30M | +1.6% |
| Q2 FY2019 | Jun 30, 2019 | $132.80M | +5.5% |
| Q1 FY2019 | Mar 31, 2019 | $143.10M | +5.4% |
| Q4 FY2018 | Dec 31, 2018 | $9.48M | -74.4% |
| Q3 FY2018 | Sep 30, 2018 | $115.40M | +2810.5% |
| Q2 FY2018 | Jun 30, 2018 | $125.90M | +3703.6% |
| Q1 FY2018 | Mar 31, 2018 | $135.71M | – |
| Q4 FY2017 | Dec 31, 2017 | $36.95M | – |
| Q3 FY2017 | Sep 30, 2017 | $3.97M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.31M | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
See a number that looks wrong?